US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche ... with Greek mythology from the name of the protein that is targeted by the RNAi drug ...

Jan 27 (Reuters) - The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai (4523.T), opens new tab and partner ... deposits of a protein called amyloid ...

Biogen has revealed encouraging phase 2 results ... is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. It is thought that CD38-expressing ...

Sage Therapeutics (NASDAQ:SAGE) has confirmed that the Alzheimer’s drug developer Biogen (NASDAQ:BIIB) has offered to buy all the outstanding shares of common stock that it currently does not ...